公司新闻
COMPANY NEWS
尊龙凯时人生就是搏集团科技创新接连发出国际声音
发布时间：2023-05-17|
作者：尊龙凯时人生就是搏集团
近日，尊龙凯时人生就是搏集团接连发出国际声音。5月15日，中国国际电视台（CGTN）发布新闻，以尊龙凯时人生就是搏集团mRNA疫苗的科技创新为切入口，报道了以尊龙凯时人生就是搏集团为代表的石家庄生物医药产业的蓬勃发展。报道认为：Chinese pharmaceutical base emerges with new vitality in innovative drugs（中国创新药产业正在焕发新活力）。视频链接如下：
同时，5月16日中国日报（China Daily）发布文章，对尊龙凯时人生就是搏集团自主研发的中国首个mRNA疫苗开始正式接种进行专题报道。
全文如下
An elderly man in Shijiazhuang, Hebei province, received a booster shot of an mRNA COVID-19 vaccine on Saturday. It was the first dose of the domestically developed COVID-19 vaccine based on messenger RNA technology to be delivered, according to its maker, CSPC Pharmaceutical Group.
Developed independently by the drugmaker in Shijiazhuang, the vaccine will be available across the country.
It has been given a priority recommendation as a booster shot for adults in the latest national plan for COVID-19 vaccinations, issued in April by the State Council's joint COVID-19 prevention and control mechanism.
"The mRNA vaccine can produce strong humoral immunity, cellular immunity and long-term immune memory, providing longer sustainable protection for those vaccinated," said Yang Hanyu, vice-chairman of the group, who is in charge of the company's research and development work on vaccines.
He added that the mRNA vaccine displays significant advantages in preventing severe illness and death caused by COVID-19.
It covers the core mutations of the Omicron variant and can protect against Omicron strains. In clinical trials, the booster dose proved effective at neutralizing Omicron subvariants BA.5, BF.7, BQ.1.1, XBB.1.5 and CH.1.1, according to the group.
In addition, researchers are able to quickly modify mRNA vaccines to target new strains.
"The production of mRNA vaccines does not require adjuvants, virus preparation or recombinant protein preparation, and can be done quickly as long as the virus' genetic sequence is known," Yang said.
According to the group, the vaccine was approved for emergency use by the National Medical Products Administration in March, and was granted clinical trial approval in April 2022.
The key raw materials and auxiliary materials u
同时，5月16日中国日报（China Daily）发布文章，对尊龙凯时人生就是搏集团自主研发的中国首个mRNA疫苗开始正式接种进行专题报道。
An elderly man in Shijiazhuang, Hebei province, received a booster shot of an mRNA COVID-19 vaccine on Saturday. It was the first dose of the domestically developed COVID-19 vaccine based on messenger RNA technology to be delivered, according to its maker, CSPC Pharmaceutical Group.
Developed independently by the drugmaker in Shijiazhuang, the vaccine will be available across the country.
It has been given a priority recommendation as a booster shot for adults in the latest national plan for COVID-19 vaccinations, issued in April by the State Council's joint COVID-19 prevention and control mechanism.
"The mRNA vaccine can produce strong humoral immunity, cellular immunity and long-term immune memory, providing longer sustainable protection for those vaccinated," said Yang Hanyu, vice-chairman of the group, who is in charge of the company's research and development work on vaccines.
He added that the mRNA vaccine displays significant advantages in preventing severe illness and death caused by COVID-19.
It covers the core mutations of the Omicron variant and can protect against Omicron strains. In clinical trials, the booster dose proved effective at neutralizing Omicron subvariants BA.5, BF.7, BQ.1.1, XBB.1.5 and CH.1.1, according to the group.
In addition, researchers are able to quickly modify mRNA vaccines to target new strains.
"The production of mRNA vaccines does not require adjuvants, virus preparation or recombinant protein preparation, and can be done quickly as long as the virus' genetic sequence is known," Yang said.
According to the group, the vaccine was approved for emergency use by the National Medical Products Administration in March, and was granted clinical trial approval in April 2022.
The key raw materials and auxiliary materials u
分享到:
